Seroprevalence and Immunoprotection Against COVID-19 in Parisian Children
AP-PEDCOVID
1 other identifier
observational
800
1 country
1
Brief Summary
The paediatric population present mild or asymptomatic form of SARS-CoV-2 infection. This study asses the frequency of patients with SARS-CoV2 Antibodies (Ab) (seroprevalence) and the neutralizing typology of those Ab (immunoprotection) in children from 7 days to 18 years of age hospitalized for no more than 4 days and whose clinical status requires blood sample regardless of the symptoms Patients are included on a given day, after information, before blood sampling performed as part of the care. 500 µL of sera, normally discarded will be kept to perform SARS-Cov2 serology.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 9, 2020
CompletedFirst Submitted
Initial submission to the registry
June 20, 2020
CompletedFirst Posted
Study publicly available on registry
July 29, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2021
CompletedJuly 29, 2020
July 1, 2020
1.7 years
June 20, 2020
July 27, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
serological test
Ab against SARS-CoV-2
48 weeks
Secondary Outcomes (2)
neutralizing Ab
48 weeks
Immuno phenotyping
48 weeks
Interventions
blood sampling is part of care
Eligibility Criteria
All hospitalized children at Assistance Publique Hôpitaux de Paris
You may qualify if:
- any child over 7 days and under 18 years of age who has been hospitalized for no more than 4 days and who has a blood sample regardless of the symptoms;
You may not qualify if:
- Any child under 7 days
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Necker Hospital
Paris, 75014, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
June 20, 2020
First Posted
July 29, 2020
Study Start
April 9, 2020
Primary Completion
December 31, 2021
Study Completion
December 31, 2021
Last Updated
July 29, 2020
Record last verified: 2020-07
Data Sharing
- IPD Sharing
- Will not share